Cargando…
Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo
Mutations in the receptor tyrosine kinase c-KIT (KIT) are frequent oncogenic alterations in melanoma and are predominantly detected in tumors of acral, mucosal, and chronically sun-damaged skin. Research indicates that melanocytes with aberrant KIT signaling can be found in the distant periphery of...
Autores principales: | Posch, Christian, Moslehi, Homayoun, Sanlorenzo, Martina, Green, Gary, Vujic, Igor, Panzer-Grümayer, Renate, Rappersberger, Klemens, Ortiz-Urda, Susana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216770/ https://www.ncbi.nlm.nih.gov/pubmed/27322141 http://dx.doi.org/10.18632/oncotarget.10001 |
Ejemplares similares
-
Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells
por: Vujic, Igor, et al.
Publicado: (2016) -
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer
por: Vujic, Igor, et al.
Publicado: (2014) -
Mutant NRAS(Q61) shares signaling similarities across various cancer types – potential implications for future therapies
por: Vujic, Igor, et al.
Publicado: (2014) -
Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma
por: Posch, C, et al.
Publicado: (2015) -
Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients
por: Posch, C, et al.
Publicado: (2014)